Search Clinical Trials

This is a multi-center, open-label, Phase 1, first-in-human (FIH), dose-escalation, and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), 以及SRK-181单独或联合抗pd -(L)1治疗局部晚期或转移性实体瘤成年患者的疗效. The study is divided into 3 treatment parts (Part A1, Part A2, and Part B) and a Long-Term Extension Phase (LTEP).

这项III期试验将检验计算机认知训练方法对乳腺癌幸存者认知障碍的疗效.

This is a study to evaluate the safety, tolerability, FTX-6058在镰状细胞病患者中的药代动力学和药效学.

PHA登记(PHAR)是一项关于肺动脉高压(PAH)和慢性血栓栓塞性肺动脉高压(CTEPH)患者的全国性研究。. PAH和CTEPH患者在全美参与PAH认证的肺动脉高压护理中心接受治疗.S.

PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH are treated according to recommended guidelines, and to see if there are certain factors that can lead to better or worse outcomes.

PHAR will include information about people with PAH and CTEPH in the U.S. who are seen at participating PHA-accredited PH Care Centers. PHAR contains data about patient care and outcomes. Specifically, data in the PHAR includes information on diagnosis; clinical status; socioeconomic status; diagnosis test results; body size; treatment information; interest in participating in clinical trials; family health and social history; and information about smoking, alcohol, or drug use. Participants are followed over time, and provide updates such as changes in therapy, how often participants need to go to the hospital, and survival. Such information may help healthcare providers provide better care.

This is a first-in-human, Phase 1/2, multicenter, 开放标签研究旨在评估vilastobart (XTX101)作为单一疗法和vilastobart (XTX101)和atezolizumab联合治疗晚期实体瘤患者的安全性和耐受性.

本研究的目的是表征间皮瘤患者使用IAG933的安全性和耐受性, NF2/LATS1/LATS2突变肿瘤和具有功能性YAP/TAZ融合的肿瘤，并确定最大耐受剂量和/或推荐剂量.

该研究旨在确定mta协同PRMT5抑制剂AMG 193与其他治疗联合给药的最大耐受剂量(MTD)或推荐联合剂量，用于转移性或局部晚期甲基硫腺苷磷酸化酶(MTAP)缺失的胃肠道成年参与者, biliary tract, or pancreatic cancers. 该研究还旨在确定AMG 193与其他疗法联合应用于转移性或局部晚期mtap缺失胃肠道的成人参与者的安全性, biliary tract, or pancreatic cancers.

The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, 和利西替尼在先前的VGN-TED-301受试者中至第24周的药效学. 这些受试者包括VGN-TED-301第24周预后无反应或在VGN-TED-301随访期间复发的受试者.

This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, 联合阿扎胞苷治疗新诊断的高危骨髓增生异常综合征(HR-MDS).

这项III期试验比较了美金刚与常规治疗在治疗原发性中枢神经系统肿瘤患者中的疗效. 美金刚可能会阻断大脑中已知导致认知功能下降的受体(神经细胞的一部分). Giving memantine may make a difference in cognitive function (attention, memory, 或其他思维过程)在儿童和青少年接受脑部放射治疗治疗原发性中枢神经系统肿瘤.

这项III期试验在低风险和中等风险的髓母细胞瘤患者中测试了两种假设. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back after treatment. 低风险成神经管细胞瘤患者的癌症复发几率通常低于中等风险成神经管细胞瘤患者. 虽然对新诊断的平均风险和低风险髓母细胞瘤的治疗通常是有效的, there are still concerns about the side effects of such treatment. 由于治疗而产生的副作用或意外的健康状况包括学习困难, hearing loss or other issues in performing daily activities. 新诊断的平均风险或低风险髓母细胞瘤的标准治疗包括手术, radiation therapy, and chemotherapy (including cisplatin). Cisplatin may cause hearing loss as a side effect. In the average-risk medulloblastoma patients, 本试验测试在标准护理化疗和放疗中加入硫代硫酸钠(STS)是否能减少听力损失. 先前对STS的研究表明，它可能有助于减少或预防顺铂引起的听力损失. In the low-risk medulloblastoma patients, 该研究测试了低强度治疗(减少辐射)是否能提供与高强度治疗相同的益处. The less intense therapy may cause fewer side effects. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. 本研究的总体目标是观察STS联合标准治疗(放疗和化疗)是否会降低成神经管细胞瘤患者的听力损失，并比较既往研究中接受STS治疗的成神经管细胞瘤患者与未接受STS治疗的患者的总体结果，以确保肿瘤的生存和复发不会恶化.

本研究的主要目的是评估RP-6306单独使用、与RP-3500联合使用或与Debio 0123联合使用在符合条件的晚期实体瘤患者中的安全性和耐受性, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

This study is a Phase III, Randomized, Controlled, 在成纤维细胞生长因子受体(FGFR)改变的受试者中，评估口服替丁哥替尼与医生选择的有效性和安全性的全球多中心研究, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma

The purpose of this study is to compare the efficacy, safety, 在自体干细胞移植(ASCT)后获得次优反应的新诊断多发性骨髓瘤(NDMM)成年参与者中，ide- cell联合来那度胺(LEN)维持与单独来那度胺维持的耐受性.

本研究旨在评估内镜下肠道再细胞化治疗对非胰岛素降糖药物控制不充分的2型糖尿病(T2D)患者的安全性和有效性.

该研究的主要目的是确定setrusumab在成骨不全患者中的剂量策略，并评估setrusumab与安慰剂在降低骨折率方面的效果.

This is a Phase 3 Randomized, Controlled, Ivonescimab联合化疗与Pembrolizumab联合化疗一线治疗转移性鳞状非小细胞肺癌的多区域研究. 主要终点是总生存期，关键次要终点包括无进展生存期. response and safety.

该研究的目的是比较扎鲁替尼加奥比妥珠单抗与来那度胺加利妥昔单抗(R^2)在复发/难治性(R/R)滤泡性淋巴瘤(FL)患者中的疗效。, 由独立审查委员会根据2014年修订的基于正电子发射断层扫描和计算机断层扫描(PET/CT)的非霍奇金淋巴瘤(NHL)国际工作组标准确定的无进展生存期来衡量。, 并比较扎鲁替尼加利妥昔单抗与R^2在R/R边缘区淋巴瘤(MZL)患者中的疗效, IRC根据基于ct的Lugano 2014标准评估无进展生存期(PFS).